drugset / Trial / NCT07851220
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study to evaluate the efficacy of inebilizumab on primary membranous nephropathy (PMN) disease activity as measured by complete remission in participants with PMN.
Timeline
- Start
- 2026-10-01
- Primary completion
- 2031-09-27
- Completion
- 2033-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inebilizumab | Monoclonal antibody | — | Intravenous |
| Comparator | Tacrolimus | Small molecule | — | Oral |